Aduro Biotech announces first patient dosed in phase 2 clinical trial of CRS-207
Aduro Biotech announced the first patient has been dosed in the company’s Phase 2 clinical trial in malignant pleural mesothelioma. The trial will evaluate tolerability, safety and efficacy of CRS-207, Aduro’s LADD based immunotherapy, in combination with KEYTRUDA®. June 28, 2017